159 related articles for article (PubMed ID: 25218905)
1. Combining targeted therapies in ovarian cancer.
Scambia G; Salutari V; Ferrandina G
Lancet Oncol; 2014 Oct; 15(11):1179-81. PubMed ID: 25218905
[No Abstract] [Full Text] [Related]
2. PARP inhibitors in BRCA mutation-associated ovarian cancer.
Clamp A; Jayson G
Lancet Oncol; 2015 Jan; 16(1):10-2. PubMed ID: 25481790
[No Abstract] [Full Text] [Related]
3. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
Li GT
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
[No Abstract] [Full Text] [Related]
4. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Tewari KS; Eskander RN; Monk BJ
Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
[TBL] [Abstract][Full Text] [Related]
5. Recurrent epithelial ovarian cancer: an update on treatment.
Foley OW; Rauh-Hain JA; del Carmen MG
Oncology (Williston Park); 2013 Apr; 27(4):288-94, 298. PubMed ID: 23781692
[TBL] [Abstract][Full Text] [Related]
6. Trebananib: an alternative anti-angiogenic strategy.
Gourley C
Lancet Oncol; 2014 Jul; 15(8):776-7. PubMed ID: 24950984
[No Abstract] [Full Text] [Related]
7. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
Dockery LE; Tew WP; Ding K; Moore KN
Gynecol Oncol; 2017 Dec; 147(3):509-513. PubMed ID: 29037805
[TBL] [Abstract][Full Text] [Related]
8. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
9. ICON-6: the danger of changing study design midstream.
Norrie J
Lancet; 2016 Mar; 387(10023):1031-1032. PubMed ID: 27025174
[No Abstract] [Full Text] [Related]
10. Ovarian cancer: TRINOVA-1, beyond VEGF inhibition.
Villanueva MT
Nat Rev Clin Oncol; 2014 Aug; 11(8):442. PubMed ID: 25001464
[No Abstract] [Full Text] [Related]
11. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
12. Planning treatment for women with recurrent epithelial ovarian cancer.
Tanner E; Armstrong DK
Oncology (Williston Park); 2013 Apr; 27(4):304, 306. PubMed ID: 23781694
[No Abstract] [Full Text] [Related]
13. Cediranib aims for a comeback.
Schmidt C
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745013
[No Abstract] [Full Text] [Related]
14. A ten-year remission maintained by 6,272 mg (3,920 mg/m2) cumulative dose of cisplatin-based chemotherapy for recurrent epithelial ovarian cancer.
Piver MS
Eur J Gynaecol Oncol; 2001; 22(6):403-5. PubMed ID: 11874068
[TBL] [Abstract][Full Text] [Related]
15. Drug combo may be effective in ovarian cancer.
Cancer Discov; 2014 Aug; 4(8):OF8. PubMed ID: 25092763
[No Abstract] [Full Text] [Related]
16. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.
Chuang YT; Chang CL
Taiwan J Obstet Gynecol; 2012 Sep; 51(3):336-41. PubMed ID: 23040913
[TBL] [Abstract][Full Text] [Related]
17. Controversy in treatment of advanced ovarian cancer.
Scambia G; Salutari V; Amadio G
Lancet Oncol; 2013 Sep; 14(10):920-1. PubMed ID: 23993374
[No Abstract] [Full Text] [Related]
18. Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
Zhong A; Zhang H; Xie S; Deng M; Zheng H; Wang Y; Chen M; Lu R; Guo L
Oncol Rep; 2018 Apr; 39(4):1747-1756. PubMed ID: 29393493
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
[TBL] [Abstract][Full Text] [Related]
20. Management of recurrent EOC: the state of the art.
Fleming GF
Oncology (Williston Park); 2013 Apr; 27(4):298, 303-4. PubMed ID: 23781693
[No Abstract] [Full Text] [Related]
[Next] [New Search]
